Despite recent declines, opioids remain commonly prescribed to about one in five \us adults who live with chronic pain as ...

Following on from the San Francisco-based firm’s attempts to sell compounded GLP-1 agonists to the weight loss market—whether ...

US drugmaker Merck & Co, known as MSD outside of North America, has scrapped a £1 billion ($1.35 billion) research center in ...

The Trump administration is weighing a draft executive order that could block the import of Chinese-made experimental ...

A new analysis from Phesi of 583 recruiting clinical trials or trials about to start involving GLP-1 receptor antagonists ...

The Trump administration has announced its intent to levy tariffs on pharmaceutical products and proposed lowering drug prices in the USA to most-favored nation prices. Based on recent trade deals ...

Danish CNS specialist Lundbeck is flexing its muscles in the competitive migraine space with a comprehensive collection of datasets being presented at the 2025 International Headache Congress, ...

Europe’s health technology assessment regime has entered a new era. Since January 2025, oncology drugs and advanced therapies ...

Japan’s largest drugmaker Takeda has presented data from two global Phase III double-blind, placebo-controlled studies of ...

Cambridge, USA-based CAMP4 Therapeutics today announced that it has entered into definitive securities purchase agreements ...

Dublin (Ireland), and Hamilton (Bermuda), dedicated to developing therapies for central nervous system and rare diseases, ...

The Chinese National Medical Products Administration (NMPA) has approved Sanofi’s (Euronext: SAN) Tzield (teplizumab). This makes it the first disease-modifying therapy in autoimmune type 1 diabetes ...